Precardiogenic Shock: A New Clinical Entity

Area of Science:

• Cardiology
• Critical Care Medicine
• Hemodynamics

Background:

• Cardiogenic shock (CS) pathogenesis has shifted from acute myocardial infarction to semi-acute deterioration with pre-existing left ventricular dysfunction.
• Pre-cardiogenic shock (Pre-CS) is defined as rapid hemodynamic decline preceding hypotension, inflammation, and end-organ failure.
• High mortality rates in CS persist, underscoring the need for improved therapeutic strategies.

Purpose of the Study:

• To define and outline the recognition of the pre-cardiogenic shock (Pre-CS) phase.
• To review management strategies for Pre-CS, focusing on supporting the failing left ventricle.
• To highlight the therapeutic potential of early intervention during Pre-CS.

Main Methods:

• This is a review article, synthesizing current knowledge on cardiogenic shock and its preceding phase.
• Literature search focused on the definition, recognition, and management of Pre-CS.
• Emphasis on pharmacologic and mechanical support strategies for left ventricular failure.

Main Results:

• Pre-CS represents a critical, identifiable period before overt cardiogenic shock.
• Early recognition and intervention in Pre-CS are essential for potentially improving patient outcomes.
• Pharmacologic and mechanical support are key management options for the failing left ventricle during Pre-CS.

Conclusions:

• Pre-CS is a distinct clinical entity offering a vital opportunity for early therapeutic intervention.
• Effective management of Pre-CS can potentially mitigate the progression to severe cardiogenic shock and reduce mortality.
• Further research into optimal Pre-CS management strategies is warranted.